Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.36 |
| ▸ | RXRB | P28702 | 1/20 | 0.36 |
| ▸ | RXRG | P48443 | 1/20 | 0.36 |
| ▸ | CYP4F2 | P78329 | 6/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 6/20 | 0.33 |
| ▸ | ATR | Q13535 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1141294 | 0.93 | RXRA (0.38) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL1141358 | 0.86 | CYP4F2 (0.39) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL1141263 | 0.86 | RXRA (0.36) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL1141337 | 0.82 | RXRA (0.41) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL17588940 | 0.81 | RXRA (0.38) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL26920565 | 0.81 | RXRA (0.38) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL29734718 | 0.81 | RXRA (0.38) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL4116261 | 0.81 | RXRA (0.38) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL138511 | 0.79 | RXRA (0.37) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL29263972 | 0.78 | ALDH1A1 (0.37) | RXRARXRBRXRGCYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2468729-B1 | Novel indazole derivative | UBE INDUSTRIES (JP) | 2013-12-25 | — | — | EP | disclosed |
| EP-1679308-B1 | NOVEL INDAZOLE DERIVATIVE | UBE INDUSTRIES (JP) | 2013-07-24 | — | — | EP | disclosed |
| US-8232308-B2 | Methods for treating a disease in which Rho kinase is involved | UBE INDUSTRIES, LTD. (JP) | 2012-07-31 | — | — | US | disclosed |
| EP-2468729-A1 | Novel indazole derivative | UBE INDUSTRIES, LTD. (JP) | 2012-06-27 | — | — | EP | disclosed |
| US-20110039891-A1 | Methods for treating a disease in which Rho kinase is involved | UBE INDUSTRIES, LTD. (JP) | 2011-02-17 | — | — | US | disclosed |
| US-7855222-B2 | Methods for treating a disease in which Rho kinase is involved | UBE INDUSTRIES, LTD. (JP) | 2010-12-21 | — | — | US | disclosed |
| US-20090264468-A1 | Methods for treating a disease in which Rho kinase is involved | UBE INDUSTRIES, LTD. (JP) | 2009-10-22 | — | — | US | disclosed |
| US-7563906-B2 | Indazole derivatives | UBE INDUSTRIES, LTD. (JP) | 2009-07-21 | — | — | US | disclosed |
| US-20070129404-A1 | Novel indazole derivatives | UBE INDUSTRIES, LTD. (JP) | 2007-06-07 | — | — | US | disclosed |
| EP-1679308-A1 | NOVEL INDAZOLE DERIVATIVE | Ube Industries, Ltd. (JP) | 2006-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264468-A1 | Methods for treating a disease in which Rho kinase is involved | RHOA, ROCK1, RHOT2 | RXRA 1731/4885RXRB 1376/4885RXRG 1908/4885 |
| US-20070129404-A1 | Novel indazole derivatives | CIT, ROCK1, ROCK2 | RXRA 1666/4885RXRB 1202/4885RXRG 1675/4885 |
| US-20110039891-A1 | Methods for treating a disease in which Rho kinase is involved | RHOA, ROCK1, ROCK2 | RXRA 1902/4885RXRB 1569/4885RXRG 2088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.